Investors have been frustrated with Allergan's reluctance to split up its chairman and CEO roles—particularly activist investor David Tepper. Now, the drugmaker says it supports an investor resolution to split the roles. The catch? It'll hold off until current chief Brent Saunders decides to leave.
